Mucpharm is an Australian founded company with its platform technology entering phase 2 in oncology (EMA and US FDA orphan designations) and phase 1b/2 extended safety and efficacy studies in muco-productive respiratory diseases (dual programs ambulant and in-hospital).

Mucpharm's lead is a first in class drug that targets the structure of mucin, both intracellular and extracellular, in cancer cells. In addition to its ability to expose the cancer cell wall, MP-171 induces apoptosis via several pathways that existing compounds do not currently address.

As it is a strong mucolytic, it has therapeutic value in respiratory diseases. Entering phase 1b clinical studies for muco-productive bronchiectasis, its secondary effects include anti-inflammatory and anti-biofilm effects, addressing a gap in management and prevention of exacerbations.

Mucpharm seeks partnering opportunities (co-development, licensing) and/or investment to expand oncology and respiratory programs.